NASDAQ:CLRB

Cellectar Biosciences - CLRB Stock Forecast, Price & News

$5.68

-0.16 (-2.74%)

(As of 08/18/2022 05:26 PM ET)

Add

Compare

Today's Range: $5.64
▼
$5.76
50-Day Range: $3.57
▼
$6.37
52-Week Range: $3.37
▼
$10.90

Volume: 23,579 shs
Average Volume: 21,623 shs
Market Capitalization: $34.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.25

Cellectar Biosciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 472.2% Upside
$32.50 Price Target
Short Interest: Healthy
0.25% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.27
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.21) to ($3.24) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

859th out of 1,119 stocks

Pharmaceutical Preparations Industry

428th out of 549 stocks

3.5

Analyst's Opinion

Consensus Rating
Cellectar Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $32.50, Cellectar Biosciences has a forecasted upside of 472.2% from its current price of $5.68.
Amount of Analyst Coverage
Cellectar Biosciences has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.25% of the float of Cellectar Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Cellectar Biosciences has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cellectar Biosciences has recently increased by 647.37%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cellectar Biosciences does not currently pay a dividend.
Dividend Growth
Cellectar Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CLRB.

2.4

News and Social Media Coverage

News Sentiment
Cellectar Biosciences has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Cellectar Biosciences this week, compared to 1 article on an average week.
Search Interest
13 people have searched for CLRB on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Cellectar Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cellectar Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.80% of the stock of Cellectar Biosciences is held by insiders.
Percentage Held by Institutions
Only 27.54% of the stock of Cellectar Biosciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cellectar Biosciences are expected to grow in the coming year, from ($4.21) to ($3.24) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cellectar Biosciences is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cellectar Biosciences is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cellectar Biosciences has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cellectar Biosciences (NASDAQ:CLRB) Stock

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Cellectar Biosciences Stock Performance

Shares of Cellectar Biosciences stock opened at $5.84 on Thursday. The company has a market capitalization of $35.68 million, a P/E ratio of -1.38 and a beta of 1.42. The company has a fifty day moving average of $4.55 and a 200 day moving average of $5.03. Cellectar Biosciences has a fifty-two week low of $3.37 and a fifty-two week high of $10.90.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. StockNews.com assumed coverage on Cellectar Biosciences in a research note on Wednesday. They issued a "sell" rating for the company. Oppenheimer reaffirmed an "outperform" rating and issued a $55.00 target price on shares of Cellectar Biosciences in a report on Monday, July 18th. Finally, Maxim Group dropped their target price on shares of Cellectar Biosciences to $12.50 in a report on Thursday, May 26th.

Receive CLRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CLRB Stock News Headlines

August 12, 2022 | americanbankingnews.com

StockNews.com Begins Coverage on Cellectar Biosciences (NASDAQ:CLRB)

August 12, 2022 | americanbankingnews.com

Equities Analysts Set Expectations for Cellectar Biosciences, Inc.'s Q3 2022 Earnings (NASDAQ:CLRB)

August 18, 2022 | Investing Trends (Ad)

Investors Look to Capitalize on the Budding Green Revolution

Lithium is the uncontested fuel of the green energy revolution. One little-known small-cap lithium mining company in a renowned South American location has started attracting interest from opportunity-minded investors.

August 11, 2022 | americanbankingnews.com

Cellectar Biosciences, Inc. Expected to Earn Q1 2023 Earnings of ($0.60) Per Share (NASDAQ:CLRB)

August 11, 2022 | americanbankingnews.com

Cellectar Biosciences (NASDAQ:CLRB) Now Covered by Analysts at StockNews.com

August 5, 2022 | baystreet.ca

Cellectar Dips on Q2 Figures

August 5, 2022 | finance.yahoo.com

Cellectar Reports Financial Results for Second Quarter 2022

August 3, 2022 | americanbankingnews.com

Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com

August 18, 2022 | Investing Trends (Ad)

Investors Look to Capitalize on the Budding Green Revolution

July 22, 2022 | finanznachrichten.de

Cellectar Biosciences: Cellectar Announces Stock Consolidation

July 21, 2022 | finance.yahoo.com

Cellectar Announces Stock Consolidation

July 19, 2022 | uk.finance.yahoo.com

Cellectar Biosciences, Inc. (CLRB)

May 12, 2022 | seekingalpha.com

Cellectar Biosciences GAAP EPS of -$0.10 in-line

May 10, 2022 | finance.yahoo.com

Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update

April 26, 2022 | marketwatch.com

Cellectar Biosciences Gets Positive DMC Review for Waldenstrom's Macroglobulinemia Treatment

April 26, 2022 | seekingalpha.com

Cellectar says committee recommends continuing trial of iopofosine in Waldenstrom’s patients

April 26, 2022 | finance.yahoo.com

Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom’s Macroglobulinemia

April 12, 2022 | finance.yahoo.com

Cellectar Biosciences Announces Key Commercial Team Appointments

March 22, 2022 | markets.businessinsider.com

CLRB To Report WM Trial Data In 2H, DICE On Watch, URGN Sees 46%-67% Revenue Growth In 2022

March 21, 2022 | msn.com

Here's Why Cellectar Biosciences Shares Are Rising

March 21, 2022 | benzinga.com

Recap: Cellectar Biosciences Q4 Earnings

March 21, 2022 | seekingalpha.com

Cellectar Biosciences GAAP EPS of -$0.43 beats by $0.01

March 21, 2022 | finance.yahoo.com

Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update

March 10, 2022 | finance.yahoo.com

Cellectar to Participate at Upcoming Banking Conferences

February 23, 2022 | seekingalpha.com

Cellectar Biosciences appoints Chad Kolean as CFO, Jarrod Longcor as COO

February 23, 2022 | finance.yahoo.com

Cellectar Biosciences Announces Executive Leadership Changes

January 17, 2022 | finance.yahoo.com

Is CanFite Biopharma Ltd (CANF) Outperforming Other Medical Stocks This Year?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CLRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CLRB Company Calendar

Last Earnings: 11/07/2021
Today: 8/18/2022
Next Earnings (Estimated): 11/14/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CLRB
CUSIP: N/A
CIK: 1279704
Web: www.cellectar.com
Phone: (608) 441-8120
Fax: 608-441-8121
Employees: 12
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $32.50
High Stock Price Forecast: $55.00
Low Stock Price Forecast: $12.50
Forecasted Upside/Downside: +274.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,120,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -89.20%
Return on Assets: -73.88%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.51
Quick Ratio: 4.51

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.08 per share
Price / Book: 1.84

Miscellaneous

Outstanding Shares: 6,110,000
Free Float: 5,939,000
Market Cap: $34.70 million
Optionable: Not Optionable
Beta: 1.42

Key Executives

Mr. James V. Caruso (Age 63)
Pres, CEO & Director
Comp: $679.25k

Mr. Jarrod Longcor (Age 49)
Chief Operating Officer
Comp: $477.45k

Mr. Chad J. Kolean CPA (Age 58)
CPA, CFO & Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CLRB Stock - Frequently Asked Questions

Should I buy or sell Cellectar Biosciences stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLRB shares.
View CLRB analyst ratings or view top-rated stocks.
What is Cellectar Biosciences' stock price forecast for 2022?: 2 analysts have issued twelve-month price targets for Cellectar Biosciences' stock. Their CLRB share price forecasts range from $12.50 to $55.00. On average, they predict the company's stock price to reach $32.50 in the next twelve months. This suggests a possible upside of 456.5% from the stock's current price.
View analysts price targets for CLRB or view top-rated stocks among Wall Street analysts.
How have CLRB shares performed in 2022?: Cellectar Biosciences' stock was trading at $6.64 at the start of the year. Since then, CLRB stock has decreased by 12.0% and is now trading at $5.84.
View the best growth stocks for 2022 here.
When is Cellectar Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our CLRB earnings forecast.
How were Cellectar Biosciences' earnings last quarter?: Cellectar Biosciences, Inc. (NASDAQ:CLRB) posted its earnings results on Sunday, November, 7th. The biopharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.10.
When did Cellectar Biosciences' stock split?: Cellectar Biosciences shares reverse split on the morning of Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Cellectar Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM).
What is Cellectar Biosciences' stock symbol?: Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."
Who are Cellectar Biosciences' major shareholders?: Cellectar Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.73%), State Street Corp (2.57%) and Franklin Resources Inc. (1.70%). Insiders that own company stock include Dov Elefant, James V Caruso, Jarrod Longcor and Stephen A Hill.
View institutional ownership trends.
How do I buy shares of Cellectar Biosciences?: Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Cellectar Biosciences' stock price today?: One share of CLRB stock can currently be purchased for approximately $5.84.
How much money does Cellectar Biosciences make?: Cellectar Biosciences (NASDAQ:CLRB) has a market capitalization of $35.68 million. The biopharmaceutical company earns $-24,120,000.00 in net income (profit) each year or ($4.22) on an earnings per share basis.
How can I contact Cellectar Biosciences?: Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The official website for the company is www.cellectar.com. The biopharmaceutical company can be reached via phone at (608) 441-8120, via email at ir@cellectar.com, or via fax at 608-441-8121.

This page (NASDAQ:CLRB) was last updated on 8/18/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Cellectar Biosciences - CLRB Stock Forecast, Price & News

Cellectar Biosciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month